Tenaya Therapeutics, INC Form 4 insider transactions

Karah Herdman Parschauer, a Director at Tenaya Therapeutics, Inc., has been granted 107,400 stock options with an exercise price of $0.4444 per share, vesting over one year.

Tomohiro Higa, SVP of Finance at Tenaya Therapeutics, sold 1,390 shares of common stock to cover tax withholding obligations related to vesting restricted stock units.

Chief Medical Officer of Tenaya Therapeutics, Whittemore Tingley, reports selling shares to cover tax obligations related to vesting restricted stock units.

CEO Faraz Ali sold 3,189 shares of Tenaya Therapeutics common stock on May 16, 2025, to cover tax withholding obligations related to vesting restricted stock units.

Tomohiro Higa, SVP of Finance at Tenaya Therapeutics, sold shares of common stock to cover tax withholding obligations related to vesting restricted stock units.

Whittemore Tingley, Chief Medical Officer of Tenaya Therapeutics, sold shares of common stock on March 10, 2025, to cover tax withholding obligations related to vesting restricted stock units.

Tenaya Therapeutics CEO Faraz Ali sold shares of common stock on March 10, 2025, to cover tax withholding obligations related to the vesting of restricted stock units.

The Column Group, through various affiliated entities, acquired a substantial number of common stock shares and warrants of Tenaya Therapeutics via a recent public offering.

David Goeddel, a director at Tenaya Therapeutics, reports the acquisition of common stock and warrants through The Column Group's participation in an underwritten public offering.

Tenaya Therapeutics CEO Faraz Ali received stock options and restricted stock units, and underwent an option repricing, as detailed in a recent SEC Form 4 filing.

A Form 4 filing reveals that Tenaya Therapeutics' Chief Medical Officer, Whittemore Tingley, received stock options and restricted stock units, and had existing options repriced, following a company-wide option repricing.

A Tenaya Therapeutics executive sold 2,258 shares of common stock at $2.12 per share to cover tax obligations related to vesting restricted stock units.

Jeffrey T. Walsh, a director at Tenaya Therapeutics, acquired 34,000 stock options on October 18, 2024, according to a recent SEC filing.

R. Sanders Williams, a director of Tenaya Therapeutics, acquired 34,000 stock options on October 18, 2024, according to a Form 4 filing with the SEC.

Catherine Stehman-Breen, a director of Tenaya Therapeutics, Inc., was granted stock options to purchase 34,000 shares of common stock.

Director Deepak Srivastava acquired 34,000 stock options in Tenaya Therapeutics, Inc. on October 18, 2024, according to a Form 4 filing.

Director Karah Herdman Parschauer reports the acquisition of stock options in Tenaya Therapeutics, Inc.

Director June Lee of Tenaya Therapeutics acquired 34,000 stock options on October 18, 2024, according to a recent SEC filing.

David V. Goeddel, a director of Tenaya Therapeutics, Inc., was granted stock options to purchase 34,000 shares of common stock.

Amy L. Burroughs, a director of Tenaya Therapeutics, acquired stock options for 34,000 shares on October 18, 2024.

Chihiro Saito, SVP of Accounting and Financial Operations at Tenaya Therapeutics, reports the acquisition of 25,000 shares and the disposal of 2,363 shares of common stock.

Chief Medical Officer of Tenaya Therapeutics, Whittemore Tingley, reports selling shares of common stock to cover tax withholding obligations related to vesting restricted stock units.

CEO Faraz Ali sold shares of Tenaya Therapeutics to cover tax withholding obligations related to vesting restricted stock units.

Tenaya Therapeutics' Chief Scientific Officer, Timothy Hoey, sold 3,300 shares of common stock at an average price of $7.0003 on March 5, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Timothy Hoey, Chief Scientific Officer of Tenaya Therapeutics, reports the acquisition of restricted stock units and stock options in the company.

Chief Medical Officer of Tenaya Therapeutics, Whittemore Tingley, reports acquisition of stock options and restricted stock units.

Leone D. Patterson, Chief Financial and Business Officer of Tenaya Therapeutics, acquired 35,000 shares of common stock and 205,000 stock options on February 23, 2024, according to a Form 4 filing.

CEO Faraz Ali received 505,000 stock options and 85,000 restricted stock units in Tenaya Therapeutics, Inc.